The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 33 sources its claims cite were checked for support.
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Open accessAbstract
BACKGROUND: -acetylgalactosamine-conjugated antisense oligonucleotide that targets the messenger RNA of apolipoprotein C-III, which inhibits triglyceride clearance. METHODS: In this phase 3, international, double-blind, randomized, placebo-controlled trial, we enrolled patients with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) and randomly assigned them in a 1:3 ratio to a 50-mg or 80-mg cohort. The patients were then randomly assigned in a 3:1 ratio to receive monthly subcutaneous olezarsen or matching placebo within each cohort. The primary outcome was the least-squares mean percent change in triglyceride level from baseline to 6 months among the patients with moderate hypertriglyceridemia, reported as the difference between each olezarsen dose group and the placebo group (the placebo-adjusted change). RESULTS: A total of 1349 patients (254 in the olezarsen 50-mg group, 766 in the olezarsen 80-mg group, and 329 in the placebo group) were included in the primary efficacy analysis. The median age was 64 years, 40% of the patients were women, and the median triglyceride level at baseline was 238.5 mg per deciliter (interquartile range, 190.5 to 307.5). At 6 months, the placebo-adjusted least-squares mean change in triglyceride level was -58.4 percentage points (95% confidence interval [CI], -65.1 to -51.7; P<0.001) in the olezarsen 50-mg group and -60.6 percentage points (95% CI, -67.1 to -54.0; P<0.001) in the olezarsen 80-mg group. The incidence of serious adverse events appeared to be similar across the trial groups. CONCLUSIONS: Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).
Overview
CoChat Summary
TL;DR
In the phase 3 ESSENCE-TIMI 73b trial, monthly olezarsen reduced triglyceride levels at 6 months in patients with moderate hypertriglyceridemia and elevated cardiovascular risk. Placebo-adjusted least-squares mean changes were −58.4 percentage points with 50 mg and −60.6 percentage points with 80 mg, with serious adverse events appearing similar across groups.
Key findings
- In the primary efficacy population (N=1349), the placebo-adjusted least-squares mean change in triglyceride level from baseline to 6 months was −58.4 percentage points (95% CI, −65.1 to −51.7; P<0.001) in the olezarsen 50-mg group and −60.6 percentage points (95% CI, −67.1 to −54.0; P<0.001) in the 80-mg group.
- At 12 months, the placebo-adjusted least-squares mean change in triglyceride level was −50.7 percentage points in both olezarsen groups (95% CI, −60.6 to −40.7 and −60.3 to −41.1; P<0.001 for both). At 6 months, 85.0% of the 50-mg group, 88.7% of the 80-mg group, and 12.5% of the placebo group had a triglyceride level below 150 mg/dL; at 12 months, the corresponding percentages were 82.8%, 85.0%, and 20.6%.
- At 6 months, placebo-adjusted changes were −61.7 and −69.8 percentage points for apolipoprotein C-III, −66.1 and −68.4 for remnant cholesterol, −21.9 and −21.7 for non-HDL cholesterol, −56.6 and −57.4 for VLDL cholesterol, +45.5 and +47.6 for HDL cholesterol, and −14.7 and −14.9 for apolipoprotein B in the 50-mg and 80-mg groups, respectively. LDL cholesterol showed no apparent change versus placebo (−1.1 and −1.5 percentage points; P=0.72 and P=0.51).
- Serious adverse events occurred in 9.4% of the 50-mg group, 13.6% of the 80-mg group, and 11.4% of the placebo group. Injection-site reactions were more common with olezarsen (15.2% and 16.2%) than placebo (1.6%). Major adverse cardiovascular events occurred in 2.8%, 5.7%, and 4.3%, respectively; acute pancreatitis occurred in 0, 3 (0.4%), and 0 patients.
Methods
- Phase 3, international, double-blind, randomized, placebo-controlled trial conducted at 160 sites in North America and Europe from November 2022 through February 2024. Patients had moderate hypertriglyceridemia (triglyceride level 150 to 499 mg/dL) plus elevated cardiovascular risk or severe hypertriglyceridemia (≥500 mg/dL).
- Patients were randomly assigned 1:3 to a 50-mg or 80-mg cohort, then 3:1 within each cohort to monthly subcutaneous olezarsen or matching placebo; treatment lasted 12 months with a 13-week safety follow-up.
- The primary efficacy population included patients with baseline triglyceride level <500 mg/dL who received at least one dose (254 in the 50-mg group, 766 in the 80-mg group, 329 in the placebo group). The primary outcome was the placebo-adjusted least-squares mean percent change in triglyceride level from baseline to 6 months, analyzed with ANCOVA including baseline triglyceride level and a retrieved dropout-based multiple-imputation approach.
Limitations
- The paper states the trial was primarily designed to assess olezarsen in moderate hypertriglyceridemia rather than across the full range of triglyceride levels; two phase 3 trials are specifically evaluating severe hypertriglyceridemia.
- The paper states efficacy and safety beyond 1 year were not assessed, and the majority of patients were White, so results may not be generalizable to other races and ethnic groups.
- Evident from the text: the trial was not powered for clinical outcomes such as major adverse cardiovascular events or acute pancreatitis, which were adjudicated but not primary endpoints; the observed fibrate interaction was noted by the authors as possibly attributable to chance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 2 Not valid · 5 Not checked · 65 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“yet highly effective therapies for reducing triglyceride levels are lacking. 5”
What the sources say
- Disputedcites [5] 5. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-806. sourceExperimental — accuracy not yet measured
The paper says the opposite about triglyceride reduction: in “Strategic approaches to lowering of triglyceride-rich lipoproteins and remnants” (page not provided), it states that fibrates effectively lower triglycerides across the range of triglyceride levels. Its “Stimulating lipolysis” section (page not provided) also reports that an APOC3-targeting therapy markedly reduced plasma triglycerides in severe hypertriglyceridaemia. The paper questions whether triglyceride lowering reduces cardiovascular risk, which is different from saying effective triglyceride-lowering therapies are lacking. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
What the sources say
- Supportedcites [6] 6. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-offunction mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32-41. source
The passage labeled Abstract says apolipoprotein C3 raises triglyceride levels by inhibiting lipoprotein-lipase hydrolysis and attenuating hepatic uptake of triglyceride-rich remnants. The Discussion repeats both mechanisms. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Partly supportedcites [7] 7. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322: 1702-5. sourceExperimental — accuracy not yet measured
The Abstract says apoC-III inhibits triglyceride hydrolysis and impairs hepatic uptake of apoB-containing lipoproteins, supporting the claim’s broad account of reduced lipoprotein clearance. Our copy does not specifically identify lipoprotein lipase as the inhibited enzyme or specify hepatic uptake of triglyceride-rich remnants. (LLM, conf=0.83)
- Partly supportedcites [8] 8. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-offunction mutations in APOC3 , triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31. sourceExperimental — accuracy not yet measured
The Discussion states that APOC3 inhibits lipoprotein lipase and delays clearance of triglyceride-rich lipoprotein remnants. It does not explicitly identify hepatic uptake as the route of that delayed clearance; that more specific mechanism is not established by the cited paper’s discussion. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moderate elevations in triglyceride levels are associated with an increased risk of atherosclerotic cardiovascular disease, 1,2,19,20”
What the sources say
- Supportedcites [1] 1. Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and metaregression analysis of randomized controlled trials. Circulation 2019; 140: 130817. source
The Background (page unavailable) says the association between triglycerides and cardiovascular risk is well established. The Results (page unavailable) report a mean baseline triglyceride level of 163 mg/dL in the triglyceride-lowering trials, consistent with the claim’s reference to moderate elevations. The paper treats triglycerides as a risk marker, not necessarily as the direct cause of atherosclerosis. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [2] 2. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-35. source
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results (page not specified) report that triglycerides were a significant predictor of ASCVD in Mendelian-randomisation models, supporting the general association. The paper does not establish the claim specifically for moderate elevations; its observational triglyceride-to-LDL-C association also became non-significant after adjustment for HDL-C. (LLM, conf=0.84)
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The Abstract reports that genetic variants associated with higher triglyceride levels are also associated with higher cardiovascular disease risk. The Discussion links triglyceride-rich ApoB particles to atherosclerotic cardiovascular risk, but it does not specifically establish the association for moderate triglyceride elevations; it emphasizes particle concentration rather than triglyceride level alone. Page numbers are unavailable in our copy. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Existing pharmacologic therapies such as statins, prescription-strength n-3 fatty acids, fibrates, and ezetimibe have only modest effects on triglyceride levels, with typical reductions ranging from less than 10% up to approximately 30%. 17”
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
Sections 8.2.2 and 8.1.2.2 report triglyceride reductions of 8% with ezetimibe and usually 10–20% with statins; section 7.5.6 reports about 30% with pharmacological doses of n-3 fatty acids. But the claimed upper range understates effects reported elsewhere in the guidelines: section 8.7.2 estimates reductions reaching 50% with fibrates, and section 8.8.2 reports up to 45% with EPA in people with high triglycerides. Page numbers are unavailable in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of serious adverse events appeared to be similar across the trial groups.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims
Create a free account to see all 81 claims and to verify the 2 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Olezarsen is an antisense oligonucleotide that utilizes triantennary GalNAc-conjugation for liver-specific delivery, allowing for lower doses and improved tolerability, with phase 2/3 and now phase 3 data (including ESSENCE TIMI 73b) showing triglyceride reductions of ~ 60% and reduced platelet-related adverse events [48, 49].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, the pooled mean difference in VLDL-C was −49.5% (95% CI, −60.1 to −38.9; I2 = 72.4%), indicating a statistically significant reduction in VLDL-C with small interfering RNA therapy (Figure 6A).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Bergmark et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VLDL-C levels were also significantly reduced in patients receiving siRNA targeting APOC3 (MD, −53.6%; 95% CI, −63.2 to −44)”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Bergmark et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, VLDL-C levels were significantly reduced in patients receiving siRNA targeting ANGPTL3 (MD, −41%; 95% CI, −52.8 to −29.1)”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Bergmark et al., 2025
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the ESSENCE–TIMI 73b trial [117], which enrolled over 1300 statin-treated patients with moderate HTG, olezarsen produced placebo-adjusted reductions of approximately 60% in triglycerides and 70% in apoC-III, along with significant decreases in non–HDL cholesterol (− 22%) and apoB (− 15%) and increases in HDL-C (+ 46%), without raising LDL-C.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [117]
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationBanks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Self-citationPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Cited by
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
“In fact, in the recent Essence-TIMI 73b study, placebo-adjusted reductions in remnant-C were 66.1% with olezarsen 50 mg and 68.4% with olezarsen 80 mg [ 25].”
InfluentialSelf-citationMarston, N., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080012 · Cited by 20
Self-citationBanach, M., Toth, P. P., Ahn, H., Bielecka-Dabrowa, A. M., Cicero, A. F. G., Covic, A. C., Dalakoti, M., Escobar, C., Fogacci, F., Gaiță, D. I., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.003 · Cited by 13
Self-citationLi, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 10
“…of three randomized controlled trials (RCTs) involving 207 patients with severe HTG reported that after an average treatment duration of 8.1 months, 84% of volanesorsen-treated patients achieved TG levels below 500 mg/dL, compared to only 35% in the placebo group [90–93]. profiles [64].”
InfluentialSelf-citationToth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 9
“In another study with olezarsen (ESSENCE TIMI 73b trial) patients with moderate HTG (TG between 150 [1.7 mmol/l] to 499 mg/dl [5.6 mmol/l]) and elevated CVD risk or with SHTG (TG ≥ 500 mg/dl [5.7 mmol/l]) were randomly assigned to olezarsen therapy at doses of 50 or 80 mg [116].”
InfluentialSelf-citation
Metadata
- Authors
- Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Li, D., Banach, M., Stroes, E., Lu, M. T., Tsimikas, S., Giugliano, R. P., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston
- Medical University of Lodz (PL)
- Amsterdam University Medical Centers (NL)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-10-02
- Volume
- 393
- Issue
- 13
- Pages
- 1279-1291
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4413853946
- Cited by
- 78
- References
- 32
- Citations by year
- 2026: 66 · 2025: 12
- FWCI
- 54.03
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- olezarsen, apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, triglyceride clearance, cardiovascular risk, severe hypertriglyceridemia, dose comparison, serious adverse events, lipid-lowering therapy, triglyceride-rich lipoproteins, hepatic VLDL secretion
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Oligonucleotides, Severity of Illness Index, Triglycerides, Hypertriglyceridemia, Oligonucleotides, Antisense, Treatment Outcome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. https://app.cochat.ai/papers/10.1056/nejmoa2507227
- The paper
- Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Li, D., Banach, M., Stroes, E., Lu, M. T., Tsimikas, S., Giugliano, R. P., & Sabatine, M. S. (2025). Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2507227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.